title: [Effect of antibody-targeted chemotherapy with pingyangmycin on prostate cancer cells in vitro].
abstract: OBJECTIVE
  To investigate the effect of antibody-targeted chemotherapy against human prostate cancer LNCaP cells in vitro.
  
  
  METHODS
  The monoclonal antibody 7E11C5.3 against human prostate cancer was conjugated to pingyangmycin (PYM), mediated by dextran T-40, and the immunoreactivity of 7E11C5.3 was determined by indirect enzyme-linked immunosorbent assay. The bacteriostatic activity of the conjugate was determined using TTC assay, and its cytotoxicity against LNCaP cells was determined by MTT assay.
  
  
  RESULTS
  The 7E11C5.3:PYM molar ratio was l:54 in the conjugate, and the immunoreactivity of 7E11C5.3 was decreased by approximately 10% to 20% after conjugation. The bacteriostatic activity of conjugated PYM was 25% of that of free PYM. The 50% inhibitory doses (IC50) of 7E11C5.3-PYM conjugate and free PYM against the in vitro cultured LNCaP cells were 9.41-/+1.98 microg/ml and 29.92-/+7.88 microg/ml, respectively.
  
  
  CONCLUSIONS
  7E11C5.3-PYM conjugate displays stronger cytotoxicity against anti-prostate cancer effects than free PYM.
authors: Department of Nuclear Medicine, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
authors: Wei-zhen
authors: WZ
authors: Chen
authors: Yong
authors: Y
authors: Zhang
authors: Chang-sheng
authors: CS
authors: Liang
authors: Yao
authors: Y
authors: Xie
authors: Qin-qiao
authors: QQ
authors: Wen
authors: Xin
authors: X
authors: Gao
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000494:pharmacology; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000494:pharmacology*; D001761:Bleomycin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D003602:Cytotoxicity, Immunologic / Q000187:drug effects* / Q000276:immunology; D016503:Drug Delivery Systems; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage / Q000494:pharmacology; D008297:Male; D011471:Prostatic Neoplasms / Q000276:immunology / Q000473:pathology
chemical_list: D000903:Antibiotics, Antineoplastic; D000911:Antibodies, Monoclonal; D018796:Immunoconjugates; D001761:Bleomycin; C025703:bleomycetin